Abstract: The present invention discloses novel photoactive compounds that may be crosslinked to target substrates. Methods for the preparation and use of the compounds, as well as compositions comprising them, are also disclosed.

Abstract: Novel 2-pyrrolylthione derived metal chelate compounds are disclosed as imaging and therapeutic agents. Compositions and methods for their preparation and use as diagnostic imaging and therapeutic agents are also disclosed.

Abstract: A series of N,N′-dimethylated N-confused porphyrin salts were synthesized through methylation of N-confused porphyrins using MeI in the presence of Na2CO3. These compounds have an intense absorption around 790 nm. It has also been shown that N,N′-dimethylated N-confused porphyrin salts can generate singlet oxygen when irradiated. They are, thus, potential sensitizers for PDT.

Abstract: Novel 2-pyrrolylthione derived metal chelate compounds are disclosed as imaging and therapeutic agents. Compositions and methods for their preparation and use as diagnostic imaging and therapeutic agents are also disclosed.

Abstract: The present invention discloses novel photoactive compounds that may be crosslinked to target substrates. Methods for the preparation and use of the compounds, as well as compositions comprising them, are also disclosed.

Abstract: Novel 2-pyrrolylthione derived metal chelate compounds are disclosed as imaging and therapeutic agents. Compositions and methods for their preparation and use as diagnostic imaging and therapeutic agents are also disclosed.

Abstract: A method for the systematic and efficient synthetic preparation and identification of metabolites of a pharmaceutical product in order to study possible toxic and/or otherwise biologically-active metabolites of such pharmaceutical products as early and conveniently as possible in the very expensive drug development process, comprising adding samples of the pharmaceutical product to a series of combinations of a synthetic metalloporphyrin (SMP) with a synthetic metalloporphyrin-co-oxidizing reagent in the presence of a suitable solvent, under specified conditions, in a manner such that each sample of pharmaceutical product is reacted with a different combination of synthetic metalloporphyrin, SMP-co-oxidizing reagent and solvent, followed by separation and isolation of the resulting oxidative products, then confirmation of the identity of metabolites from the pre-identified oxidative products by appropriate animal model studies, and subjecting the actual metabolites prepared in larger quantities by the above m

Abstract: Disclosed are tetraphenyl porphyrins which are beta-substituted by fluoro or chloro and/or bear electronegative substituents on the phenyl including one or two water solubilizing substituents. The new porphorins are particularly suitable as catalysts in a variety of oxidative reactions and methods.

Abstract: Disclosed are tetraphenyl porphyrins which are beta-substituted by fluoro or chloro and/or bear electronegative substituents on the phenyl including one or two water solubilizing substituents. The new porphorins are particularly suitable as catalysts in a variety of oxidative reactions and methods.

Abstract: O-alkoxyphenols are produced from cyclohexanone or cyclohexanol by chlorination of cyclohexanone or cyclohexanol to trichlorocyclohexanone and reaction of the trichlorocyclohexanone with an aliphatic, monohydric alcohol having one to four carbon atoms and a base to form an intermediate compound or compounds which are further reacted to convert the intermediate compound or compounds to an o-alkoxyphenol.

Abstract: O-alkoxyphenols are produced from cyclohexanone or cyclohexanol by chlorination of cyclohexanone or cyclohexanol to trichlorocyclohexanone and reaction of the trichlorocyclohexanone with an aliphatic, monohydric alcohol having one to four carbon atoms and a base to form an intermediate compound or compounds which are further reacted to convert the intermediate compound or compounds to an o-alkoxyphenol.